Respiratory syncytial virus (RSV) remains the leading cause of hospitalization in Canadian infants. While hospital-based administration of nirsevimab may be addressing in-season births in many regions in Canada, many infants born between April and November and those previous not immunized remain at risk unless proactively identified and immunized by primary care. In this short 5-minute microlearning session, Dr. Jane Healey outlines practical, evidence-based strategies to close the RSV protection gap and ensure that no infant enters RSV season unprotected.
This program has received an unrestricted educational grant or in-kind support from Sanofi Canada.
